AUROPHARMA Q1 FY27 results at a glance
AUROBINDO PHARMA LTD Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹9,106 cr |
|---|
| Revenue YoY | +16.9% |
|---|
| Operating profit | ₹1,394 cr |
|---|
| Operating margin | 15.3% |
|---|
| Net profit | ₹1,033 cr |
|---|
| Net profit YoY | +25.2% |
|---|
| Net profit QoQ | +12.1% |
|---|
| Net margin | 11.3% |
|---|
| Basic EPS | ₹17.86 |
|---|
| TTM revenue | ₹34,254 cr |
|---|
| TTM net profit | ₹3,689 cr |
|---|
| TTM net margin | 10.8% |
|---|
AUROPHARMA Q1 FY27 results: what the numbers say
AUROBINDO PHARMA LTD (AUROPHARMA) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹9,106 cr and a net profit of ₹1,033 cr, translating into earnings per share of ₹17.86.
Compared with the same quarter a year earlier, revenue grew by +16.9% and net profit grew strongly by +25.2%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹1,394 cr, an operating margin of 15.3% versus 15.4% a year ago — a contraction of 0.1 percentage points.
AUROPHARMA quarter-wise results table
Revenue
₹9,106 cr
+16.9% YoY
Net profit
₹1,033 cr
+25.2% YoY
Operating profit
₹1,394 cr
+16.4% YoY
AUROBINDO PHARMA LTD (AUROPHARMA) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹9,106 cr | ₹1,394 cr | ₹1,033 cr | 15.3% | 11.3% | ₹17.86 | +25.2% | +12.1% |
| Q4 FY262026-03-31 | ₹8,752 cr | ₹1,322 cr | ₹921 cr | 15.1% | 10.5% | ₹15.86 | +2.0% | +1.2% |
| Q3 FY262025-12-31 | ₹8,605 cr | ₹1,309 cr | ₹910 cr | 15.2% | 10.6% | ₹15.67 | — | +10.4% |
| Q1 FY262025-06-30 | ₹7,792 cr | ₹1,198 cr | ₹825 cr | 15.4% | 10.6% | ₹14.20 | — | -8.7% |
| Q4 FY252025-03-31 | ₹8,381 cr | ₹1,347 cr | ₹903 cr | 16.1% | 10.8% | ₹15.56 | — | — |
| TTM (last 4 quarters) | ₹34,254 cr | ₹5,223 cr | ₹3,689 cr | 15.2% | 10.8% | ₹63.59 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
AUROPHARMA quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
AUROBINDO PHARMA LTD quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹9,106 cr | ₹8,752 cr | ₹8,605 cr | ₹7,792 cr | ₹8,381 cr |
|---|
| Total expenses | ₹7,712 cr | ₹7,429 cr | ₹7,296 cr | ₹6,594 cr | ₹7,034 cr |
|---|
| Gross profit | ₹5,479 cr | ₹5,322 cr | ₹5,123 cr | ₹4,553 cr | ₹4,953 cr |
|---|
| Operating profit (EBIT) | ₹1,394 cr | ₹1,322 cr | ₹1,309 cr | ₹1,198 cr | ₹1,347 cr |
|---|
| Operating margin | 15.3% | 15.1% | 15.2% | 15.4% | 16.1% |
|---|
| Interest cost | ₹102 cr | ₹98.21 cr | ₹92.77 cr | ₹97.75 cr | ₹115 cr |
|---|
| Profit before tax | ₹1,515 cr | ₹1,291 cr | ₹1,339 cr | ₹1,207 cr | ₹1,335 cr |
|---|
| Tax expense | ₹483 cr | ₹370 cr | ₹429 cr | ₹383 cr | ₹432 cr |
|---|
| Effective tax rate | 31.9% | 28.7% | 32.0% | 31.7% | 32.4% |
|---|
| Net profit (PAT) | ₹1,033 cr | ₹921 cr | ₹910 cr | ₹825 cr | ₹903 cr |
|---|
| Net profit margin | 11.3% | 10.5% | 10.6% | 10.6% | 10.8% |
|---|
| Basic EPS | ₹17.86 | ₹15.86 | ₹15.67 | ₹14.20 | ₹15.56 |
|---|
| Diluted EPS | ₹17.86 | ₹15.86 | ₹15.67 | ₹14.20 | ₹15.56 |
|---|
AUROPHARMA results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +16.9% | +4.4% | — | — | — |
|---|
| Revenue QoQ | +4.0% | +1.7% | +10.4% | -7.0% | — |
|---|
| Operating profit YoY | +16.4% | -1.9% | — | — | — |
|---|
| Operating profit QoQ | +5.4% | +1.1% | +9.3% | -11.1% | — |
|---|
| Net profit YoY | +25.2% | +2.0% | — | — | — |
|---|
| Net profit QoQ | +12.1% | +1.2% | +10.4% | -8.7% | — |
|---|
| EPS YoY | +25.8% | +1.9% | — | — | — |
|---|
| EPS QoQ | +12.6% | +1.2% | +10.4% | -8.7% | — |
|---|
AUROPHARMA annual results history
Full-year performance for AUROBINDO PHARMA LTD, useful for reading each quarter in context.
AUROBINDO PHARMA LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹33,385 cr | ₹31,378 cr | ₹28,705 cr | ₹24,617 cr |
|---|
| Total expenses | ₹28,192 cr | ₹26,330 cr | ₹24,263 cr | ₹22,080 cr |
|---|
| Gross profit | ₹19,060 cr | ₹17,637 cr | ₹15,468 cr | ₹12,717 cr |
|---|
| Operating profit (EBIT) | ₹5,193 cr | ₹5,048 cr | ₹4,442 cr | ₹2,538 cr |
|---|
| Operating margin | 15.6% | 16.1% | 15.5% | 10.3% |
|---|
| Interest cost | ₹352 cr | ₹440 cr | ₹268 cr | ₹129 cr |
|---|
| Profit before tax | ₹5,112 cr | ₹5,066 cr | ₹4,380 cr | ₹2,613 cr |
|---|
| Tax expense | ₹1,609 cr | ₹1,583 cr | ₹1,211 cr | ₹685 cr |
|---|
| Effective tax rate | 31.5% | 31.2% | 27.6% | 26.2% |
|---|
| Net profit (PAT) | ₹3,505 cr | ₹3,486 cr | ₹3,173 cr | ₹1,928 cr |
|---|
| Net profit margin | 10.5% | 11.1% | 11.1% | 7.8% |
|---|
| Basic EPS | ₹60.34 | ₹59.81 | ₹54.16 | ₹32.90 |
|---|
| Diluted EPS | ₹60.34 | ₹59.81 | ₹54.16 | ₹32.90 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹9,106 cr against ₹7,792 cr in Q1 FY26, and ₹8,752 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +4.0%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹7,712 cr, or 84.7% of revenue, with operating profit grew +16.4% year on year.
Margins, tax and profitability
Net profit of ₹1,033 cr works out to a net margin of 11.3% compared with 10.6% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, AUROBINDO PHARMA LTD reported profit before tax of ₹1,515 cr, a tax charge of ₹483 cr (effective rate 31.9%), interest cost of ₹102 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹921 cr in Q4 FY26 to ₹1,033 cr in Q1 FY27, a change of +12.1%.
Trailing twelve months and annual context
Across the trailing four quarters AUROBINDO PHARMA LTD has generated revenue of ₹34,254 cr and net profit of ₹3,689 cr, a trailing net margin of 10.8%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹33,385 cr with net profit of ₹3,505 cr and EPS of ₹60.34, versus the prior year where revenue grew +6.4% and profit grew +0.5%.
What to watch in the next AUROPHARMA quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
AUROBINDO PHARMA LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
AUROPHARMA results coverage
No results report published for AUROPHARMA yet — our desk covers each quarter within minutes of the filing.
More on AUROPHARMA
AUROPHARMA quarterly results FAQs
What were AUROBINDO PHARMA LTD (AUROPHARMA) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), AUROBINDO PHARMA LTD reported revenue of ₹9,106 cr and net profit of ₹1,033 cr, a change of +25.2% year on year on +16.9% revenue growth. EPS stood at ₹17.86.
What is AUROPHARMA profit margin in Q1 FY27?
AUROBINDO PHARMA LTD posted a net profit margin of 11.3% and an operating margin of 15.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹34,254 cr and net profit ₹3,689 cr.
Did AUROPHARMA results beat the previous quarter?
AUROBINDO PHARMA LTD net profit changed +12.1% quarter on quarter, from ₹921 cr in Q4 FY26 to ₹1,033 cr in Q1 FY27.
When are AUROBINDO PHARMA LTD (AUROPHARMA) quarterly results?
AUROBINDO PHARMA LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see AUROPHARMA latest quarterly results?
Results coverage for AUROPHARMA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the AUROPHARMA stock page.
What is AUROBINDO PHARMA LTD annual revenue and profit?
For FY26, AUROBINDO PHARMA LTD reported full-year revenue of ₹33,385 cr and net profit of ₹3,505 cr, with EPS of ₹60.34.
How many quarterly results has AUROPHARMA declared recently?
Past results dates for AUROPHARMA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
